• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

    11/14/24 4:41:12 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARS alert in real time by email
    SC 13G 1 fintarsus.htm 13G HTML File DOCUMENT TYPE SC 13G
    TEXT


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934


    Name of Issuer: TARSUS PHARMACEUTICALS INC
    _____________________________________________________
    Title of Class
    of Securities: Common Stock

    CUSIP Number: 87650L103

    1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON

    Prudential Financial, Inc. 22-3703799

    2.) MEMBER OF A GROUP: (a) N/A
    (b) N/A

    3) SEC USE ONLY:



    4) PLACE OF ORGANIZATION: New Jersey

    NUMBER OF SHARES BENEFICIALLY OWNED BY REPORTING PERSON WITH:

    5) Sole Voting Power: 46,811 See Exhibit A
    6) Shared Voting Power: 2,248,589 See Exhibit A
    7) Sole Dispositive Power: 46,811 See Exhibit A
    8) Shared Dispositive Power: 2,248,589 See Exhibit A

    9) AGGREGATE AMOUNT BENEFICIALLY OWNED: 2,295,400 See Exhibit A

    10) AGGREGATE AMOUNT IN ROW (9) EXCLUDES SHARES: Not applicable

    11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 6.0 See Exhibit A

    12) TYPE OF REPORTING PERSON: HC

    ITEM 1(a). NAME OF ISSUER:

    TARSUS PHARMACEUTICALS INC

    ITEM 1(b). ADDRESS OF ISSUER'S EXECUTIVE OFFICES:

    15440 LAGUNA CANYON ROAD IRVINE, CA 92618

    ITEM 2(a). NAME OF PERSON FILING:

    Prudential Financial, Inc.

    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

    751 Broad Street
    Newark, New Jersey 07102-3777

    ITEM 2(c). CITIZENSHIP:

    New Jersey

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:

    Common Stock

    ITEM 2(e). CUSIP NUMBER:

    87650L103

    ITEM 3. The Person filing this statement is a Parent Holding Company as
    defined in Section 240.13d-1(b)(1)(ii)(G) of the Securities Exchange
    Act of 1934.

    ITEM 4. OWNERSHIP:

    (a) Number of Shares
    Beneficially Owned: 2,295,400 See Exhibit A


    (b) Percent of Class: 6.0


    (c) Powers                No. Of Shares
    ----------- --------------------
    Sole power to vote or 46,811 See Exhibit A to direct the vote
    Shared power to vote or 2,248,589 See Exhibit A to direct the vote
    Sole power to dispose or 46,811 See Exhibit A to direct disposition
    Shared power to dispose 2,248,589 See Exhibit A or to direct disposition

    ITEM 5. OWNERSHIP OF 5% OR LESS OF A CLASS:

    Not Applicable

    ITEM 6. OWNERSHIP OF MORE THAN 5% ON BEHALF OF
    ANOTHER PERSON:

    Our clients may have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities which are the subject of this filing.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE
    SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING
    REPORTED ON BY THE ULTIMATE PARENT COMPANY:

    See Exhibit A

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF
    MEMBERS OF THE GROUP:

    Not Applicable

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

    Not Applicable

    ITEM 10. CERTIFICATION:

    By signing below, Prudential Financial, Inc. certifies that, to the best of its
    knowledge and belief, the securities referred to above were acquired
    and are held in the ordinary course of business and were not acquired
    and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired
    and are not held in connection with or as a participant in any transaction
    having that purpose or effect.


    The filing of this statement should not be construed as an admission that
    Prudential Financial, Inc. is, for purposes of Sections 13 or 16 of the Securities
    Exchange Act of 1934, the beneficial owner of such shares.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief,
    Prudential Financial, Inc. certifies that the information set forth in this
    statement is true, complete and correct.

    PRUDENTIAL FINANCIAL, INC.

    By:Richard Baker
    Second Vice President

    Date:11-14-2024
    As of:9-30-2024

    Exhibit A
    --------------

    ITEM 4. OWNERSHIP:

      Through its parent/subsidiary relationship, Prudential Financial, Inc. may
      be deemed the beneficial owner of the same securities as the Item 7 listed
      subsidiaries and may have direct or indirect voting and/or investment
      discretion over 2,295,400 shares.
      

    These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Prudential Financial, Inc. is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares.




    ITEM 7. IDENTIFICATION/CLASSIFICATION:

    Prudential Financial, Inc. is a Parent Holding Company and the indirect parent of the following subsidiaries, who are the beneficial owners of the number and percentage of securities which are the subject of this filing as set forth next to their names:
    

    
    
    Subsidiaries Number of Shares Percentage
    The Prudential Insurance Company of America IC 13,325 0.0
    Jennison Associates LLC IA 2,178,580 5.7
    PGIM, Inc. IA 101,000 0.3
    PGIM Quantitative Solutions LLC IA 2,495 0.0
    PRUCO Securities, LLC IA 0 0.0





    Get the next $TARS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARS

    DatePrice TargetRatingAnalyst
    11/20/2023$19.00Neutral
    Goldman
    7/18/2023$44.00Outperform
    William Blair
    5/18/2023Buy
    Guggenheim
    8/1/2022$40.00Overweight
    Barclays
    12/21/2021$40.00Buy
    HC Wainwright & Co.
    11/23/2021$55.00Outperform
    Oppenheimer
    10/8/2021$50.00 → $65.00Strong Buy
    Raymond James
    6/29/2021$39.00 → $50.00Strong Buy
    Raymond James
    More analyst ratings

    $TARS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tarsus to Participate in Upcoming Investor Conferences

      IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ETH.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20th, at 12:00 p.m. PT / 3:00 p.m. ETStifel Virtual Ophthalmology Forum on Tuesday, May 27th, at 7:30 a.m. PT / 10:30 a.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours a

      5/8/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

      GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte

      5/5/25 6:27:00 AM ET
      $ELAN
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

      Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announce

      5/1/25 4:05:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Goldberg Andrew D. bought $18,960 worth of shares (1,000 units at $18.96), increasing direct ownership by 50% to 3,000 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      12/19/23 6:30:59 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President/CEO and Board Chair Azamian Bobak R. sold $300,000 worth of shares (6,000 units at $50.00) (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/26/25 4:47:19 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Mottiwala Aziz sold $505,856 worth of shares (10,565 units at $47.88), decreasing direct ownership by 14% to 65,057 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/20/25 9:49:54 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Neervannan Seshadri sold $363,142 worth of shares (7,583 units at $47.89), decreasing direct ownership by 9% to 79,682 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/20/25 9:49:35 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

      Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:29:16 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Tarsus Pharmaceuticals with a new price target

      Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00

      11/20/23 7:55:38 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Tarsus Pharmaceuticals with a new price target

      William Blair initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $44.00

      7/18/23 7:27:56 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Tarsus Pharmaceuticals

      Guggenheim initiated coverage of Tarsus Pharmaceuticals with a rating of Buy

      5/18/23 7:36:58 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Financials

    Live finance-specific insights

    See more

    $TARS
    Leadership Updates

    Live Leadership Updates

    See more
    • Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

      Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announce

      5/1/25 4:05:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to ad

      4/24/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

      Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data; first pharmacologic treatment to demonstrate functional improvements in Meibomian Gland Disease and patient symptoms in Demodex blepharitis patients Continued advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, the next category-creating opportunity in eye care Management to host conference call today, February 25, 2025, at 5 a.m. PT / 8 a.m. ET IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced

      2/25/25 7:00:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

      Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access

      11/13/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

      IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris

      11/5/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

      IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra

      4/24/23 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

      SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:41:12 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:35:55 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 3:05:35 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.

      SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      5/7/25 11:27:44 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.

      10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

      5/1/25 4:10:36 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

      5/1/25 4:07:27 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care